secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wellgistics Health, Inc. (WGRX)
CIK:        0002030763
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001493152-26-009702
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wellgistics Health secures preferred EBV pricing via Kare PharmTech revenue-share deal
--------------------------------------------------------------------------------

- Entered Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC on March 6, 2026 for product 'KARE Verify' (insurance eligibility & benefits verification).
- Revenue split: 50% to Wellgistics, 50% to PharmTech; term is 36 months unless earlier terminated.
- Wellgistics makes preferred EBV pricing available immediately through EinsteinRx AI hub; expects revenue stream beginning Q2 2026.
- EBV market forecast to grow from $2.39B in 2025 to $3B in 2030 per The Business Research Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer